Rosiglitazone decreases blood pressure and renal injury in a female mouse model of systemic lupus erythematosus

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 296, Issue 4, 2009, Pages

  Venegas Pont, Marcia ^a   Sartori Valinotti, Julio C ^a   Maric, Christine ^a   Racusen, Lorraine C ^b   Glover, Porter H ^a   McLemore Jr , Gerald R ^a   Jones, Allison V ^a   Reckelhoff, Jane F ^a   Ryan, Michael J ^a,c  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

^c UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

Author keywords

Endothelin; Glomerulosclerosis; Inflammation; Lupus; Proliferator activated receptor gamma

Indexed keywords

ALBUMIN; CREATININE; ENDOTHELIN; OSTEOPONTIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSI; ROSIGLITAZONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE MEASUREMENT; CELL COUNT; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE URINE LEVEL; FEMALE; GLOMERULOSCLEROSIS; HYPERTENSION; KIDNEY CORTEX; MACROPHAGE; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYSTEMIC LUPUS ERYTHEMATOSUS; URINALYSIS;

ALBUMINURIA; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CHEMOKINE CCL2; DISEASE MODELS, ANIMAL; ENDOTHELIN-1; FEMALE; HYPERTENSION; KIDNEY; KIDNEY DISEASES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MACROPHAGES; MICE; MONOCYTES; OSTEOPONTIN; PPAR GAMMA; RNA, MESSENGER; THIAZOLIDINEDIONES;

EID: 65949088801     PISSN: 03636119     EISSN: 15221490     Source Type: Journal    
DOI: 10.1152/ajpregu.90992.2008     Document Type: Article

References (64)

1. Al-Herz A, Ensworth S, Shojania K, Esdaile JM. Cardiovascular risk factor screening in systemic lupus erythematosus. J Rheumatol 30: 493-496, 2003. (Pubitemid 36301940)
2. Aprahamian T, Bonegio RG, Richez C, Yasuda K, Chiang LK, Sato K, Walsh K, Rifkin IR. The peroxisome proliferator-activated receptor gamma agonist rosiglitazone ameliorates murine lupus by induction of adiponectin. J Immunol 182: 340-346, 2009.
3. Bakris GL, Ruilope LM, McMorn SO, Weston WM, Heise MA, Freed MI, Porter LE. Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria. J Hypertens 24: 2047-2055, 2006.
4. Bertin P, Kamdem J, Bonnet C, Arnaud M, Treves R. Captopril-induced lupus. Clin Exp Rheumatol 11: 695, 1993.
5. Blank M, Shoenfeld Y. Experimental models of systemic lupus erythematosus: anti-dsDNA in murine lupus. Rheumatology 44: 1086-1089, 2005. (Pubitemid 41236013)
6. Bolten CW, Payne MA, McDonald WG, Blanner PM, Chott RC, Ghosh S, Arhancet GB, Staten NR, Gulve EA, Sullivan PM, Hromockyj AE, Colca JR. Thiazolidinediones inhibit the progression of established hypertension in the Dahl salt-sensitive rat. Diab Vasc Dis Res 4: 117-123, 2007. (Pubitemid 47167495)
7. Bravo Y, Quiroz Y, Ferrebuz A, Vaziri ND, Rodriguez-Iturbe B. Mycophenolate mofetil administration reduces renal inflammation, oxidative stress, and arterial pressure in rats with lead-induced hypertension. Am J Physiol Renal Physiol 293: F616-F623, 2007. (Pubitemid 47358134)
8. Buchanan TA, Meehan WP, Jeng YY, Yang D, Chan TM, Nadler JL, Scott S, Rude RK, Hsueh WA. Blood pressure lowering by pioglitazone. Evidence for a direct vascular effect. J Clin Invest 96: 354-360, 1995.
9. Burnet FM, Holmes MC. The natural history of the NZB/NZW F1 hybrid mouse: a laboratory model of systemic lupus erythematosus. Australas Ann Med 14: 185-191, 1965.
10. Burnett R, Ravel G, Descotes J. Clinical and histopathological progression of lesions in lupus-prone (NZB x NZW) F1 mice. Exp Toxicol Pathol 56: 37-44, 2004. (Pubitemid 39486844)
11. Casey TP. Immunosuppression by cyclophosphamide in NZB x NZW mice with lupus nephritis. Blood 32: 436-444, 1968.
12. Chan TM, Li FK, Tang CS, Wong RW, Fang GX, Ji YL, Lau CS, Wong AK, Tong MK, Chan KW, Lai KN. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong- Guangzhou Nephrology Study Group. N Engl J Med 343: 1156-1162, 2000.
13. Crosby MB, Zhang J, Nowling TM, Svenson JL, Nicol CJ, Gonzalez FJ, Gilkeson GS. Inflammatory modulation of PPAR gamma expression and activity. Clin Immunol 118: 276-283, 2006. (Pubitemid 43199667)
14. De CC, Amiri F, Iglarz M, Cohn JS, Touyz RM, Schiffrin EL. Synergistic vascular protective effects of combined low doses of PPARα and PPARγ activators in angiotensin II-induced hypertension in rats. Br J Pharmacol 151: 45-53, 2007. (Pubitemid 46676010)
15. Diep QN, El Mabrouk M, Cohn JS, Endemann D, Amiri F, Virdis A, Neves MF, Schiffrin EL. Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-gamma. Circulation 105: 2296-2302, 2002. (Pubitemid 34535341)
16. Dobrian AD, Schriver SD, Khraibi AA, Prewitt RL. Pioglitazone prevents hypertension and reduces oxidative stress in diet-induced obesity. Hypertension 43: 48-56, 2004.
17. Domsic R, Maksimowicz-McKinnon K, Manzi S. Prevention of cardiovascular disease in patients with rheumatic diseases. Best Pract Res Clin Rheumatol 20: 741-756, 2006. (Pubitemid 44350116)
18. Donadio JV Jr, Hart GM, Bergstralh EJ, Holley KE. Prognostic determinants in lupus nephritis: a long-term clinicopathologic study. Lupus 4: 109-115, 1995.
19. Efrati S, Berman S, Ilgiyeav E, Averbukh Z, Weissgarten J. PPAR-γ activation inhibits angiotensin II synthesis, apoptosis, and proliferation of mesangial cells from spontaneously hypertensive rats. Nephron Exp Nephrol 106: e107-e112, 2007. (Pubitemid 47165837)
20. Elmarakby AA, Quigley JE, Imig JD, Pollock JS, Pollock DM. TNF-α inhibition reduces renal injury in DOCA-salt hypertensive rats. Am J Physiol Regul Integr Comp Physiol 294: R76-R83, 2008.
21. Faedda R, Palomba D, Satta A, Pirisi M, Tanda F, Bartoli E. Immunosuppressive treatment of the glomerulonephritis of systemic lupus. Clin Nephrol 44: 367-375, 1995. (Pubitemid 26002815)
22. Frostegard J. SLE, atherosclerosis and cardiovascular disease. J Intern Med 257: 485-495, 2005. (Pubitemid 40776508)
23. Frostegard J. Systemic lupus erythematosus and cardiovascular disease. Lupus 17: 364-367, 2008.
24. Giles TD, Sander AG. Effects of thiazolidinediones on blood pressure. Curr Hypertens Rep 9: 332-337, 2007. (Pubitemid 47377033)
25. Guan Y, Hao C, Cha DR, Rao R, Lu W, Kohan DE, Magnuson MA, Redha R, Zhang Y, Breyer MD. Thiazolidinediones expand body fluid volume through PPARγ stimulation of ENaC-mediated renal salt absorption. Nat Med 11: 861-866, 2005. (Pubitemid 41161118)
26. Hahn BH, McMahon M. Atherosclerosis and systemic lupus erythematosus: the role of altered lipids and of autoantibodies. Lupus 17: 368-370, 2008.
27. Herlitz H, Svalander C, Tarkowski A, Westberg G. Effect of captopril on murine systemic lupus erythematosus disease. J Hypertens Suppl 6: S684-S686, 1988. (Pubitemid 19067444)
28. Iglarz M, Touyz RM, Amiri F, Lavoie MF, Diep QN, Schiffrin EL. Effect of peroxisome proliferator-activated receptor-α and -γ activators on vascular remodeling in endothelin-dependent hypertension. Arterioscler Thromb Vasc Biol 23: 45-51, 2003. (Pubitemid 36091624)
29. Ikeda T, Nakayama D, Gomi T, Sakurai J, Yamazaki T, Yuhara M. Captopril, an angiotensin I-converting enzyme inhibitor, decreases proteinuria in hypertensive patients with renal diseases. Nephron 52: 72-75, 1989. (Pubitemid 19098524)
30. Jonsson CA, Svensson L, Carlsten H. Beneficial effect of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil on survival and severity of glomerulonephritis in systemic lupus erythematosus (SLE)-prone MRLlpr/lpr mice. Clin Exp Immunol 116: 534-541, 1999. (Pubitemid 29258108)
31. Komajda M, Curtis P, Hanefeld M, Beck-Nielsen H, Pocock SJ, Zambanini A, Jones NP, Gomis R, Home PD. Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study) [Online]. Cardiovasc Diabetol 7: 10, 2008.
32. Kummer MP, Heneka MT. PPARs in Alzheimer's disease (Online). PPAR Res 2008: 403896, 2008.
33. Kuryliszyn-Moskal A, Klimiuk PA, Ciolkiewicz M, Sierakowski S. Clinical significance of selected endothelial activation markers in patients with systemic lupus erythematosus. J Rheumatol 35: 1307-1313, 2008.
34. LaMarca BB, Cockrell K, Sullivan E, Bennett W, Granger JP. Role of endothelin in mediating tumor necrosis factor-induced hypertension in pregnant rats. Hypertension 46: 82-86, 2005. (Pubitemid 40946495)
35. Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA Jr, Jansen- McWilliams L, D'Agostino RB, Kuller LH. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 145: 408-415, 1997. (Pubitemid 27084212)
36. Mikdashi JA, Kittner Handwerger BS. The impact of antihypertensive therapy on the prevalence of cerebrovascular events in systemic lupus erythematosus. American College of Rheumatology 2004 meeting, San Antonio, TX, October 16-21, 2004, Abstract 380.
37. Nakamura T, Ebihara I, Tomino Y, Koide H. Effect of a specific endothelin A receptor antagonist on murine lupus nephritis. Kidney Int 47: 481-489, 1995.
38. Nakamura T, Ushiyama C, Shimada N, Hayashi K, Ebihara I, Koide H. Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients. J Diabetes Complications 14: 250-254, 2000.
39. Oates JC, Reilly CM, Crosby MB, Gilkeson GS. Peroxisome proliferator- activated receptor gamma agonists: potential use for treating chronic inflammatory diseases. Arthritis Rheum 46: 598-605, 2002.
40. Perez De LG, De WC, Cohen CD, Nieto E, Molina A, Banas B, Luckow B, Vicente AB, Mampaso F, Schlondorff D. Angiotensin inhibition reduces glomerular damage and renal chemokine expression in MRL/lpr mice. J Pharmacol Exp Ther 307: 275-281, 2003. (Pubitemid 37151918)
41. Petri M, Perez-Gutthann S, Spence D, Hochberg MC. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med 93: 513-519, 1992.
42. Ratliff NB, III. Captopril induced lupus. J Rheumatol 29: 1807-1808, 2002.
43. Rudofsky UH, Dilwith RL, Roths JB, Lawrence DA, Kelley VE, Magro AM. Differences in the occurrence of hypertension among (NZB X NZW)F1, MRL-lpr, and BXSB mice with lupus nephritis. Am J Pathol 116: 107-114, 1984. (Pubitemid 14087098)
44. Ryan MJ, Didion SP, Mathur S, Faraci FM, Sigmund CD. PPARγ agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice. Hypertension 43: 661-666, 2004. (Pubitemid 38282444)
45. Ryan MJ, McLemore, GR Jr. Hypertension and impaired vascular function in a female mouse model of systemic lupus erythematosus. Am J Physiol Regul Integr Comp Physiol 292: R736-R742, 2007.
46. Ryan MJ, McLemore, GR Jr, Hendrix ST. Insulin resistance and obesity in a mouse model of systemic lupus erythematosus. Hypertension 48: 988-993, 2006.
47. Sarafidis PA, Bakris GL. Protection of the kidney by thiazolidinediones: an assessment from bench to bedside. Kidney Int 70: 1223-1233, 2006.
48. Sartori-Valinotti JC, Iliescu R, Yanes LL, Dorsett-Martin W, Reckelhoff JF. Sex differences in the pressor response to angiotensin II when the endogenous renin-angiotensin system is blocked. Hypertension 51: 1170-1176, 2008.
49. Sasser JM, Sullivan JC, Hobbs JL, Yamamoto T, Pollock DM, Carmines PK, Pollock JS. Endothelin A receptor blockade reduces diabetic renal injury via an anti-inflammatory mechanism. J Am Soc Nephrol 18: 143-154, 2007. (Pubitemid 46053429)
50. Sertznig P, Seifert M, Tilgen W, Reichrath J. Present concepts and future outlook: function of peroxisome proliferator-activated receptors (PPARs) for pathogenesis, progression, and therapy of cancer. J Cell Physiol 212: 1-12, 2007. (Pubitemid 46876399)
51. Sherer Y, Gorstein A, Fritzler MJ, Shoenfeld Y. Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. Semin Arthritis Rheum 34: 501-537, 2004. (Pubitemid 40288129)
52. Song J, Knepper MA, Hu X, Verbalis JG, Ecelbarger CA. Rosiglitazone activates renal sodium- and water-reabsorptive pathways and lowers blood pressure in normal rats. J Pharmacol Exp Ther 308: 426-433, 2004. (Pubitemid 38134200)
53. 2+ currents and not endothelial nitric oxide production Diabetes 46: 659-664, 1997.
54. Teplitsky V, Shoenfeld Y, Tanay A. The renin-angiotensin system in lupus: physiology, genes and practice, in animals and humans. Lupus 15: 319-325, 2006. (Pubitemid 44032706)
55. Uchida A, Nakata T, Hatta T, Kiyama M, Kawa T, Morimoto S, Miki S, Moriguchi J, Nakamura K, Fujita H, Itoh H, Sasaki S, Takeda K, Nakagawa M. Reduction of insulin resistance attenuates the development of hypertension in sucrose-fed SHR. Life Sci 61: 455-464, 1997. (Pubitemid 27305583)
56. Urowitz MB, Gladman DD, Ibanez D, Berliner Y. Modification of hypertension and hypercholesterolaemia in patients with systemic lupus erythematosus: a quality improvement study. Ann Rheum Dis 65: 115-117, 2006. (Pubitemid 41815651)
57. Viljoen A. New approaches in the diagnosis of atherosclerosis and treatment of cardiovascular disease. Recent Patents Cardiovasc Drug Discov 3: 84-91, 2008.
58. Wardle EN. PPAR: Receptors that regulate inflammation. Saudi J Kidney Dis Transpl 15: 1-6, 2004.
59. Watanabe K, Komatsu J, Kurata M, Inaba S, Ikeda S, Sueda S, Suzuki J, Kohara K, Hamada M. Improvement of insulin resistance by troglitazone ameliorates cardiac sympathetic nervous dysfunction in patients with essential hypertension. J Hypertens 22: 1761-1768, 2004. (Pubitemid 39141969)
60. Xiong Z, Huang H, Li J, Wang H. [PPAR-gamma expression in the kidney of actively proliferating glomerulonephritis] [Abstract]. Beijing Da Xue Xue Bao 35: 499-502, 2003.
61. Yosefy C, Magen E, Kiselevich A, Priluk R, London D, Volchek L, Viskoper RJ Jr. Rosiglitazone improves, while Glibenclamide worsens blood pressure control in treated hypertensive diabetic and dyslipidemic subjects via modulation of insulin resistance and sympathetic activity. J Cardiovasc Pharmacol 44: 215-222, 2004. (Pubitemid 38982165)
62. Yoshio T, Masuyama J, Mimori A, Takeda A, Minota S, Kano S. Endothelin-1 release from cultured endothelial cells induced by sera from patients with systemic lupus erythematosus. Ann Rheum Dis 54: 361-365, 1995.
63. Zhang F, Sowers JR, Ram JL, Standley PR, Peuler JD. Effects of pioglitazone on calcium channels in vascular smooth muscle. Hypertension 24: 170-175, 1994. (Pubitemid 24239424)
64. Zhang H, Zhang A, Kohan DE, Nelson RD, Gonzalez FJ, Yang T. Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention. Proc Natl Acad Sci USA 102: 9406-9411, 2005. (Pubitemid 40923576)